The Antidote: Inside the World of New Pharma (78 page)

Hurter and,
159
–61

Ken Boger on,
278
–79

VIP and,
158
–59

Goldman Sachs,
185
–86,
247
,
276
,
380
–81

Google,
153
–54,
321

Gordon, Marshall,
368
–69

Graham, Camilla,
265
,
379

Grassley, Charles,
369
–71

Graves, Kurt,
163
–64,
184
,
207
,
287

earnings calls and,
175
–77

HCV and,
171
,
176
–77,
199
,
208

relations between board and,
164
,
188
–89

Great Recession,
199
,
240
,
247

Greenwood, Jim,
202

Grootenhuis, Peter,
118
–19,
121
,
180

GS-7977,
363

Hadida, Sabine,
119
–21,
125
,
181

Hamburg, Margaret,
361

Hartmann, Victor,
123
–24,
127
,
130
–31,
184

Harvard Business School (HBS),
22
,
96
,
108
,
205
,
314

CF case study and,
68
–70

Vertex’s portfolio process and,
92
,
97
–98,
101

Hawking, Stephen,
154
–55

health care,
203
,
246
,
252
,
312

Clinton and,
11
,
26

financial stress in,
377
–78

Obama’s legislation on,
5
,
195
,
214
,
217
,
219
–20,
237
,
366
,
372
,
377

heart disease,
56
,
88
,
93
,
99
,
121
,
129
,
197

helicases,
39
,
44
,
49

hemolytic anemia,
221

Henderson, Bart,
49

Henderson, Jeff,
240
,
327
–28

hepatitis C:

of Alam’s father,
129
,
275

causes of,
21
,
273
,
292

comparisons between CF and,
165
,
179
,
181
,
346
,
350
–51,
382

deaths due to,
42
,
274
,
292
,
374

education on,
277
,
292

as epidemic,
21
,
42
,
77
,
139
,
163
–65,
167
,
203

politics and,
163
,
165
–67,
203
,
213
–14,
300

public-health dimensions of,
373
–74

relapses of,
139
–40,
274
,
348
,
363

hepatitis C drug therapies:

all-oral regimens for,
261
–62,
288
,
300
,
314
,
324
–25,
328
,
333
,
341
–42,
345
,
347
–49,
355
–56,
363
,
372
–73,
376
,
379

ALS 2200 and,
372
,
375

animal testing and,
94
–95,
106

BILN-2061 and,
82
,
105
–6,
129
–31

collaborations on,
22
–23,
32
,
37
,
42
–44,
48
,
61
–64,
68
,
75
–76,
78
,
82
–83,
107
–11

combination therapies for,
148
,
150
,
171
,
176
,
183
,
215
,
220
–22,
262
,
275
–76,
300
,
325
,
327
,
333
,
347
–48,
358
,
363
,
378

DDIs and,
256
–57,
266
–68,
285

EASL meeting and,
261
–63

EPO and,
192
,
200
,
208
–9,
264
,
266
–67

FDA and,
22
,
61
,
130
,
135
,
137
–38,
150
–51,
159
,
165
–66,
183
,
230
,
264
–76,
283
,
285
,
373

IMPDH and,
93
,
99
,
109
,
183

Incivek and,
see
Incivek

Kwong and,
39
–41,
44
,
49
,
62
–63,
82
,
94
–96,
101
,
106
–7,
148
,
183
,
262
,
356

Merck and,
22
,
34
,
44
,
82
,
200
,
207
–8,
216
–18,
223
,
226
–31,
233
,
238
,
244
,
249
,
256
,
260
–61,
263
–64,
284
,
307
,
316
,
347
–49,
357

merimepodib and,
93
–94,
99
–100,
102
,
105
,
108
,
128

Murcko and,
32
–35,
37
,
63

nucs and,
151
,
182
–83,
220
,
261
–62,
299
,
325
,
347
,
349
,
352
–53,
355
,
358
,
360
,
362
–63,
372
–73,
378
–79

patent issues and,
47
–48,
101

Pharmasset and,
182
–83,
220
,
261
–62,
324
–25,
327
,
329
,
342
,
347
–51,
353
–56,
359
,
363

and proteases and protease inhibitors,
22
–23,
32
–35,
37
–38,
40
,
44
,
49
,
61
–62,
76
–77,
82
–83,
91
,
93
–95,
101
,
105
,
128
,
131
,
140
,
148
,
151
,
158
,
172
,
176
,
220
,
276
,
289
,
336

PSI-7977 and,
327
,
329
,
347
–51,
355
–56

resistance and,
62
–63,
137
,
140
,
147
,
150
,
209
,
220
–21

shorter-duration treatments in,
135
,
137
–38,
149
–50,
276

VCH-222 and,
199
,
220

Victrelis (boceprevir) and,
172
,
200
,
208
,
212
,
228
–31,
238
,
245
,
260
,
263
–68,
273
,
275
–77,
282
–88,
299
,
307
,
311
,
315
–16,
341
–42,
354
,
374

VX-222 and,
215
,
220
,
262
,
299
–300,
325
,
347
,
355
,
358
,
362
–63,
383

hepatitis C virus (HCV):

comparisons between HIV and,
21
–23,
33
–34,
38
,
64
,
147
,
163
–65,
183
,
220
,
262
,
286
,
356
–57

genetics and,
32
–34,
39
,
47
–48,
61
,
94
–95,
147
,
183
,
373

genotypes of,
137
,
142
–43,
150
,
261
,
275
,
348
,
355
–56.
358
,
373

replication of,
63
,
101

screening assays and,
61
–62

structure of,
22
–23

testing for,
21
,
203
,
213
,
277
,
292
–93,
300
,
351
,
374

Herper, Matthew,
251

high-throughput screening,
66
,
78
,
81
,
86
,
89
,
205

Hoechst Marion Roussel (HMR),
47
,
49
,
51
–52,
65

Hoffman–La Roche,
see
Roche

Houghton, Michael,
47
–48

Howton, Ty,
367
,
370

Huckman, Mike,
193
–94,
216
–17,
237

human bronchial epithelial (HBE) cells,
118
–21,
125
–26,
142
–43,
179
,
302
,
344

human immunodeficiency virus (HIV),
49
,
63
,
127
,
193
,
219
,
256
,
350
,
365

Agenerase and,
25
–26,
28
–32,
35
–36,
46
–47,
50
–51,
56
,
65
,
77
,
85
,
92
,
97
–98,
102
,
147
,
186
,
225

collaborations and,
12
–13,
24
–27,
31
–32,
35
–36,
46
,
50
,
53
,
77
,
85
,
98

combination therapies for,
85
,
146
–47,
230
,
357

comparisons between HCV and,
21
–23,
33
–34,
38
,
64
,
147
,
163
–65,
183
,
220
,
262
,
286
,
356
–57

Cumbo and,
224
–26,
229
,
242

Lexiva and,
77
,
97
–98,
102
,
111
,
186

Merck and,
5
,
14
–15,
19
,
24
–26,
30
–31,
36
,
49
,
94
,
357

Murcko and,
13
–14,
17
–18,
28
–29,
91
,
335

patents and,
30
–32,
35
–36,
357

PK and,
25
,
35

in prisons,
224
,
229

and proteases and protease inhibitors,
13
–15,
17
–20,
24
–32,
35
–36,
46
,
50
,
76
–77,
82
,
147
–48,
183
,
220
,
230
,
242
,
357

resistance and,
137
,
140
,
147
–48

Vertex councils on,
18
–19,
25

Vertex’s reorganization and,
64
–65

VX-328 and,
18
–19

VX-330 and,
18
–20,
25

Humira,
317
,
357

Huntington’s disease,
201
,
380

Hurter, Trish,
336

HCV and,
112
–14,
124
,
132
–33,
159
–61

Incivek and,
168
–69,
232
,
239
,
289

management style and skills of,
134
–35,
158
–61

hypertension,
4
,
55
,
261
,
316

Idenix,
288
,
352
,
360
,
373

Imclone,
216
,
223

immunosuppressants,
128
,
177
,
227
,
257
,
277

IMS Health,
299
,
307
,
313
,
315
,
324

data misreported by,
327
–32,
339
–40

Incivek (telaprevir, VX-950),
295

AdComm and,
226
–27,
230
–31,
238
,
240
,
243
–44,
255
–58,
264
–65,
268
–76,
292
,
344

all-oral HCV treatment and,
300
,
341
–42,
347
,
363
,
372

animal studies and,
112
,
132

approvals of,
275
–77,
284
–85,
289
,
316
,
341
–42,
344